Pijet, Barbara
Konopka, Anna
Rejmak, Emilia
Stefaniuk, Marzena
Khomiak, Danylo
Bulska, Ewa
Pikul, Stanisław
Kaczmarek, Leszek
Funding for this research was provided by:
National Center of Research and Development (PBS/A8/36/2015)
Article History
Received: 13 August 2020
Accepted: 11 November 2020
First Online: 4 December 2020
Competing interests
: BP, AK, ER and LK applied for a patent for marimastat for the treatment of epileptogenesis, and this invention was licensed to Pikralida (SP) for its further market-oriented development (patent application no:PCT/IB2019/055040; filing date: 17.06.2019; title: Use of marimastat for preventing and/or treating epileptogenesis; inventors: Leszek Kaczmarek, Barbara Pijet-Binkiewicz, Anna Konopka, Emilia Rejmak-Kozicka; applicants: Instytut Biologii Doświadczalnej im. M. Nenckiego PAN, Uniwersytet Warszawski; status: patent pending). Specific aspect of manuscript covered in patent application—in patent application the following data was described: specific inhibition of MMP-9 activity in vitro/in vitro, marimastat blood–brain barrier penetration, therapeutic use of marimastat in mouse model of epileptogenesis. MS, EB, DK and SP declare that there is no competing interest relevant to the publication of this paper.